Skip to content

Allotment

Mahamaya Lifesciences Limited

The Mahamaya Lifesciences IPO will open for subscription on November 11, 2025, and close on November 13, 2025. This is a book-built issue, through which the company aims to raise approximately ₹70.44 crore. The IPO comprises a fresh issue of ₹64.28 crore and an offer for sale of up to 5,40,800 equity shares, each with a face value of ₹10.

The price band for the IPO is set between ₹108 and ₹114 per share. The issue allocation is structured with 50% for QIBs, 15% for HNIs, and 35% for retail investors. The shares are scheduled to be listed on the BSE on November 18, 2025, with the allotment expected on November 14, 2025.

On the financial front, Mahamaya Lifesciences has reported a revenue of ₹267.17 crore in FY2025, up from ₹162.83 crore in FY2024. Net profit increased to ₹12.94 crore in FY2025, compared to ₹5.22 crore in FY2024, reflecting healthy growth in operations and profitability.

Given the company’s consistent financial performance, the Mahamaya Lifesciences IPO appears suitable for long-term investors.

Mahamaya Lifesciences Limited IPO & Charts
₹114

0%

Open

₹114

HIgh - Low

₹114

Previous Close

₹114

Total Traded Value

0

52 Weeks High

₹114

52 Weeks Low

₹114

Updates On

Nov 5, 2025

IPO. Open

Nov 11, 2026

IPO. Close

Nov 13, 2026

IPO. Price

₹114.00

IPO Market price

₹266.82 Cr

IPO Details

IPO Date 18 Nov
IPO Listing Date 18 Nov
IPO Face Value ₹10.00 per share
IPO Price Range ₹114.00
IPO Issue Size 61,78,800 shares
IPO Sale Type Fresh Capital-cum-Offer for Sale
Employee Discount ₹10.00
IPO Issue Type Bookbuilding IPO
IPO Listing BSE-SME Platform
Share Holding Pre Issue 1,77,66,200 shares

IPO Timeline

IPO Open Date 11 Nov
IPO Close Date 13 Nov
IPO Allotment (Tentative) 14 Nov
Refunds 17 Nov
Credit to Demat Account 17 Nov
IPO Listing Date 18 Nov

IPO Reservation

Category Offer
QIB Shares Offered 29,28,000
NII (HNI) Shares Offered 8,82,000
Retail Shares Offered 20,59,200

IPO Lot Size

Investors can bid for a minimum of 2,400 shares, with additional shares in multiples of 1,200.

Application Lots Share Amount
Retail (Min) 2 2,400 ₹2,73,600
Retail (Max) 2 2,400 ₹2,73,600
S-HNI (Min) 3 3,600 ₹4,10,400
S-HNI (Max) 7 8,400 ₹9,57,600
B-HNI (Min) 8 9,600 ₹10,94,400
About Company

Mahamaya Lifesciences Limited, incorporated in 2002, is a leading company engaged in the manufacture, registration, and export of crop protection products and bioproducts aimed at enhancing crop and soil health and supporting the farming community for improved productivity.

The company specializes in pesticide formulations and supplies bulk technical products to Indian agrochemical companies as well as multinational corporations (MNCs). Mahamaya imports carefully researched molecules, registers them with the Central Insecticides Board and Registration Committee (CIBRC), and markets them as technical and value-added formulations for domestic manufacturers and MNCs.

With a strong focus on global markets, Mahamaya has actively registered products in countries such as the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, providing high-quality products along with necessary data support for registration.

Product Portfolio

* Bulk Formulations Sales:

Acetamiprid, SP Buprofezin, SC Emamectin Benzoate, SG Imidacloprid, SC Paraquat Dichloride

* Technical Sales:

Acetamiprid Technical 99% Min, Atrazine Technical 95% Min, Imidacloprid Technical 95% Min, Emamectin Benzoate Technical 95% Min

* Branded Products (Major Own Brands):

MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, UCHIT EW 370

* Export Sales – Formulations:

Wiper (Sulphur 80% WDG), Lancha (Pendimethalin 50% EC), Tolfen (Tolfenpyrad 15% EC), Typic (80% Sulphur WG)

Competitive Strengths

* Experienced management team with deep expertise in agrochemical formulations

* Ability to introduce vital products for Indian agriculture

* Development of export opportunities across multiple countries

* Strong brand development capabilities

* Cordial relationships with suppliers of raw materials

* Focus on sustainability and innovation in agriculture

Since setting up its own manufacturing plant in December 2021 at Dahej, Gujarat, Mahamaya has expanded its presence across multiple Indian states including Punjab, Haryana, Rajasthan, Uttar Pradesh, Gujarat, Maharashtra, Andhra Pradesh, and Telangana, while exporting products to countries like Turkey, Egypt, and UAE.

Mahamaya Lifesciences has established itself as a trusted partner in agriculture by providing high-quality, registered crop protection products to support farmers both in India and abroad.

Mahamaya Lifesciences Ltd. reported a 64% increase in revenue and a 148% rise in profit after tax (PAT) between the financial years ending March 31, 2024, and March 31, 2025.

Company Financials (Consolidated)

Assets 218.87 188.35 112.07
Total Income 84.04 267.17 162.83
Profit After Tax 4.1 12.94 5.22
EBITDA 8.04 24.64 13.36
NET Worth 53.5 49.42 24.66
Reserves and Surplus 35.73 31.66 23.41
Total Borrowing 57.72 58.11 54.63

Key Performance Indicator (KPI)

ROE 34.94%
ROCE 23.15%
Debt/Equity 1.08
RoNW 26.19%
PAT Margin 4.84%
EBITDA Margin 9.22%
Price to Book Value 9.4
IPO Objective

IPO Objects of the Issue

S.No. Objects of the ipo Resources Detail IPO Amount
1 Funding capital expenditure requirements for the purchase of equipment/machineries 29.42
2 To meet out the expenses of Working Capital Requirement 18
3 To meet out the General Corporate Purposes; 8.26
4 Offer for Sale (OFS) -

Contact Details

Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/

Detail Registrar

IPO Registrar
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: mahamaya.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/

FAQ

The Mahamaya Lifesciences IPO opened on November 11, 2025, closed on November 13, 2025, with allotment on November 14 and listing on BSE SME on November 18, 2025.

The IPO price is fixed at ₹114 per share. Retail investors must apply for a minimum of 2,400 shares, requiring a total investment of ₹2,73,600.

The IPO size is approximately ₹70 crore, comprising a fresh issue of shares and an offer for sale of up to 5,40,800 equity shares.

The company reported strong growth, with revenue increasing to ₹267.17 crore and profit after tax rising to ₹12.94 crore in FY2025 from ₹5.22 crore in FY2024.

With consistent financial growth, strong agrochemical expertise, expanding export presence, and healthy profitability ratios, the IPO appears suitable for long-term investors seeking exposure to the agrochemical sector.

Compare:

Back To Top